Charlie Hatton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2348260/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature, 2012, 483, 603-607.	27.8	6,473
2	Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20007-20012.	7.1	927
3	High-throughput oncogene mutation profiling in human cancer. Nature Genetics, 2007, 39, 347-351.	21.4	927
4	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 2010, 42, 715-721.	21.4	642
5	MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20411-20416.	7.1	574
6	Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway. PLoS Genetics, 2012, 8, e1002772.	3.5	489
7	Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discovery, 2011, 1, 78-89.	9.4	455
8	Drug-sensitive <i>FGFR2</i> mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8713-8717.	7.1	329
9	Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. PLoS ONE, 2009, 4, e7887.	2.5	316
10	A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell, 2019, 36, 660-673.e11.	16.8	231
11	Therapeutic targeting of preleukemia cells in a mouse model of <i>NPM1</i> mutant acute myeloid leukemia. Science, 2020, 367, 586-590.	12.6	145
12	EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation. Chemistry and Biology, 2014, 21, 1463-1475.	6.0	128
13	An Alternative Approach to ChIP-Seq Normalization Enables Detection of Genome-Wide Changes in Histone H3 Lysine 27 Trimethylation upon EZH2 Inhibition. PLoS ONE, 2016, 11, e0166438.	2.5	108
14	Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes. Cancer Research, 2016, 76, 1975-1988.	0.9	89
15	High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood, 2011, 117, 2433-2440.	1.4	71
16	Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients. Journal of Molecular Diagnostics, 2014, 16, 660-672.	2.8	70
17	Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. ELife, 2016, 5, .	6.0	70
18	Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. Journal of Biological Chemistry, 2016, 291, 13014-13027.	3.4	58

CHARLIE HATTON

#	ARTICLE	IF	CITATIONS
19	Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. Clinical Cancer Research, 2016, 22, 4259-4270.	7.0	44
20	The menin-MLL1 interaction is a molecular dependency in <i>NUP98</i> -rearranged AML. Blood, 2022, 139, 894-906.	1.4	42
21	Colorectal Cancers from Distinct Ancestral Populations Show Variations in BRAF Mutation Frequency. PLoS ONE, 2013, 8, e74950.	2.5	34
22	Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response. Cancer Research, 2016, 76, 1313-1319.	0.9	26
23	Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. Blood, 2020, 136, 1983-1988.	1.4	25
24	MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape. Molecular Cell, 2022, 82, 1140-1155.e11.	9.7	21
25	YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia, 2022, 36, 426-437.	7.2	18
26	IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nature Cancer, 2022, 3, 595-613.	13.2	16
27	MOZ and Menin–MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor. Cancer Discovery, 2022, 12, 1804-1823.	9.4	10
28	Using UMLS metathesaurus concepts to describe medical images: dermatology vocabulary. Computers in Biology and Medicine, 2006, 36, 89-100.	7.0	9